Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by brad129on Dec 11, 2020 11:20pm
201 Views
Post# 32092198

RE:RE:RE:RE:RE:Why an analyst forecast of $5.13 CAD?

RE:RE:RE:RE:RE:Why an analyst forecast of $5.13 CAD?

according to Noel, 

" other platforms are not accurately capturing the data and may be incorrectly multiplying certain data by the US$/C$ exchange rate."



davewho wrote: Thanks Brad, Szls reports Q numbers in US$ but the 12 mon target price has always been C$ as far as I understood and TD showed it as C$. The latest change to the target I would guess is from the estimate for covid testing rev given during the CC. $19-$31mUS in 9-12 mons. Although you can call and ask him. Since SZLS main exchange is the TSX I would assume we are talking C$ targets. Yes you are correct we did miss in Q3. Hopefully Q4 reported in May2021 shows a vast improvement in rev numbers to justify his target

 

<< Previous
Bullboard Posts
Next >>